Notícias e Atividades da Candel Therapeutics
Presença
Executivos
Veja o organograma con seus 29 executivos principais
Biografias mais buscadas da Candel Therapeutics
- Paul-Peter Tak, Director, President and Chief Executive Officer
- Chris Martell, Director
- Edward Benz, Director
Recentes movimentos de executivos em Candel Therapeutics
- Mark Sims, ingressou na Companhia como Chief Commercial Officer (Notícia publicada em 25 de junho de 2026).
- Allison Nylen antes Director, Finance, foi promovido a Corporate Controller (Notícia publicada em 14 de janeiro de 2026).
- Kristin Kennedy, Corporate Controller, deixou a Companhia (Notícia publicada em 14 de janeiro de 2026).
Criar um alerta
para seguir os movimentos de executivos da Candel Therapeutics.
Biotecnologia
Candel Therapeutics possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).
Popular M&A news in Biotecnologia
- Eli Lilly has announced the acquisition of AtaiBeckley (publicado em 17 de julho de 2026).
- GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
- Clearside Biomedical has gone out of its bankruptcy protection (publicado em 15 de julho de 2026).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Candel Therapeutics
- Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer | Candel Therapeutics, Inc
- Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting | Candel Therapeutics, Inc
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Candel Therapeutics, Inc
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Candel Therapeutics, Inc
- Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors | Candel Therapeutics, Inc
- Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | Candel Therapeutics, Inc
- Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting | Candel Therapeutics, Inc
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Candel Therapeutics, Inc
- Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston | Candel Therapeutics, Inc
- Candel Therapeutics Announces Proposed $100 Million Public Offering | Candel Therapeutics, Inc
- View more press releases Close
Redes sociais sobre Candel Therapeutics
- Candel Therapeutics na Wikipedia, Google News e Yahoo Finance
- Candel Therapeutics na LinkedIn, X (Twitter) e YouTube
